Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219128 · ClinicalTrials.gov registry record · Phase 3
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
NCT00219128 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 671 participants.
The verdict
NCT00219128, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
Study Summary
Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
Interventions
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219128
The ClinicalTrials.gov registry entry for NCT00219128 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aliskiren is the first listed.
NCT00219128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219128 about?
NCT00219128 is a clinical study titled "A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.". Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
What is the current status of trial NCT00219128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2004-11. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00219128?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219128?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.